Photo from MiNK Therapeutics/LinkedIn
May 17, 2024, 04:19
MiNK Therapeutics’ Q1 report
MiNK Therapeutics shared on LinkedIn: .
“This quarter we made significant strides across our iNKT cell programs, including generating clinical data from our agenT-797 program, strengthening our financial position, and advancing our innovative next-generation therapies.
Read more in our Q1 report.”
Source: MiNK Therapeutics/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14